Search Results

Development of this comprehensive bispecific antibody program included policy development; toxicity management; creation of patient and staff education documents; creation of clinician tools like a toxicity scoring and charting tool and an electronic order set that segregates treatment options; and a monitoring system to safely transition patients from inpatient to outpatient care.

In this episode, CANCER BUZZ speaks with Brittney Baer, BSN, RN, patient care coordinator, immune effector cells, at Vanderbilt University Medical Center’s Vanderbilt-Ingram Cancer Center about key strategies and solutions to prioritize patient quality of life by addressing barriers to holistic survivorship care.

Advancements in clinical data and research have shown the immunotherapeutic potential of bispecific antibodies as treatment for hematologic cancers and solid tumors. In this episode, CANCER BUZZ speaks with Aaron Cumpston, PharmD, pharmacy clinical specialist in hematologic malignancies and bone marrow transplant and Christine Barrett, PharmD, BCOP, medical oncology clinical pharmacy specialist at …

Dr. Sanjay Juneja explores how—with many cancers now being treated like a chronic disease—it may be time to cancel the term “a cure for cancer.”

In this episode, hear from two experts in cancer immunotherapy on the exciting potential of TIL Cell Therapy in melanoma and beyond.

Presented at the 63rd ASH Annual Meeting, December 11-14, 2021, in Atlanta, GA.

Learn about dermatology’s role in the cancer care continuum and how cancer teams can better integrate dermatology into the immunotherapy care process.

Through its immunotherapy initiative, ACCC has developed a medical wallet card for patients on immunotherapy for cancer. A downloadable print-ready PDF enables cancer programs & practices to have copies printed.

We explore how immunotherapy clinical trials have been affected by the pandemic and what cancer programs can do to safely and effectively administer clinical trials.

Learn about the mental health implications of treatment with cancer immunotherapy, and how cancer care providers can better integrate mental health awareness into the IO care continuum.

How do interest specialists outside the field of oncology in participating in an inter-specialty immune-related adverse events (irAEs) tumor board? Cleveland Clinic discovered the key is to recruit physician champions who are not oncologists.

Johns Hopkins was one of the first institutions to use immunotherapies to treat intractable cancers. Because IO therapies can affect any of the body's organ systems, there was early recognition of the value of having a multidisciplinary team of organ specialists who could bring their expertise to the treatment of patients experiencing immune-related adverse events (irAEs).

We sat down with journalist Mary Elizabeth Williams, one of the first patients treated with combination immunotherapy, to discuss her experience as an IO patient and how to bridge communication gaps among patients, doctors, and researchers.

ACCC’s Immuno-Oncology Institute has developed the Survivorship Care Plans for Patients Receiving Immunotherapy as a resource for cancer programs and practices. and describes processes for developing survivorship care plans (SCPs) for patients treated with immunotherapy, effective practices in SCP design, and considerations for SCP delivery for this patient population.

Learn why a trip to the emergency department is different for patients who receive immunotherapy for cancer, what information helps ED clinicians, and what busy emergency department providers need to know about immune-related adverse events.

Learn about the transition from immunotherapy into post-treatment survivorship, how it differs from chemotherapy, and why coordination and communication among providers, patients, and caregivers is essential.

Pseudoprogression has emerged as a distinct radiologic response pattern best defined as radiologic tumor progression from baseline that is not confirmed as progression on subsequent radiologic assessment.

Hyperprogressive disease (HPD) has recently been reported as a novel pattern of aggressive tumor growth following exposure to immune checkpoint blockade drugs such as anti-PD-1 and anti-PD-L1 antibodies.

ACCC Immuno-Oncology Institute Executive Committee Chair Lee Schwartzberg, MD, FACP, highlights his top picks for compelling, potentially practice-changing immunotherapy abstracts presented during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr. Schwartzberg is Chief, Division of Hematology Oncology; Professor of Medicine, University of Tennessee; and Executive Director, West …

The Association of Community Cancer Centers recently spoke with Robyn Stacy-Humphries, MD, who was diagnosed with lymphoma in 2011, about her experience of treatment with CAR T-cell therapy in a clinical trial at the James Cancer Hospital at Ohio State University in Columbus, Ohio.